Arena Capital Advisors’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Arena Capital Advisors’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-300,000	Closed	-$3.03M	–	158
2022 Q4	$3.03M	Hold	300,000	–	–	1.65%	22
2022 Q3	$2.98M	Hold	300,000	–	–	0.9%	36
2022 Q2	$2.97M	Hold	300,000	–	–	0.75%	46
2022 Q1	$2.96M	Hold	300,000	–	–	0.45%	79
2021 Q4	$2.95M	Hold	300,000	–	–	0.27%	119
2021 Q3	$2.92M	Buy	300,000 +202,728	+208%	+$1.96M	0.23%	136
2021 Q2	$941K	Buy	+97,272	New	+$945K	0.08%	246

Arena Capital Advisors's BIOT Position: Q1 2023 in Review

Arena Capital Advisors sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 300,000 shares — an estimated $3.03M sold.

Arena Capital Advisors first reported a position in BIOT in Q2 2021 and held it in 7 quarters. The position peaked at $3.03M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Arena Capital Advisors reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Arena Capital Advisors sold 300,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $3.03M.
Arena Capital Advisors first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Arena Capital Advisors's Biotech Acquisition Company Class A Ordinary Shares position peaked at $3.03M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Arena Capital Advisors's 13F filing for Q1 2023, filed 12 May 2023.